Should I buy or sell Pulmonx stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LUNG shares. View LUNG analyst ratings or view top-rated stocks .

What is Pulmonx's stock price target for 2024?

6 brokerages have issued 12-month price objectives for Pulmonx's stock. Their LUNG share price targets range from $12.00 to $18.00. On average, they expect the company's stock price to reach $15.83 in the next twelve months. This suggests a possible upside of 110.8% from the stock's current price. View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts .

How have LUNG shares performed in 2024?

Pulmonx's stock was trading at $12.75 at the beginning of 2024. Since then, LUNG shares have decreased by 41.1% and is now trading at $7.51. View the best growth stocks for 2024 here .

When is Pulmonx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our LUNG earnings forecast .

How can I listen to Pulmonx's earnings call?

Pulmonx will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link .

How were Pulmonx's earnings last quarter?

Pulmonx Co. (NASDAQ:LUNG) posted its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. The business had revenue of $19.30 million for the quarter, compared to analyst estimates of $18.24 million. Pulmonx had a negative net margin of 88.60% and a negative trailing twelve-month return on equity of 46.63%. Pulmonx's revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.38) EPS.

What guidance has Pulmonx issued on next quarter's earnings?

Pulmonx issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $78.9 million.

When did Pulmonx IPO?

Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are Pulmonx's major shareholders?

Pulmonx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin , David Aaron Lehman , Derrick Sung , Geoffrey Beran Rose , Glendon E French III , John Mckune, Richard Ferrari and Scientific Corp Boston. View institutional ownership trends .

How do I buy shares of Pulmonx?

Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LUNG

Pulmonx (LUNG) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free LUNG Stock Alerts

$7.51

+0.01 (+0.13%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.35
▼
$7.76
50-Day Range: $7.42
▼
$14.65
52-Week Range: $7.21
▼
$14.84

Volume: 347,792 shs
Average Volume: 515,362 shs
Market Capitalization: $289.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.83

Get Pulmonx alerts:

Pulmonx MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 110.8% Upside
$15.83 Price Target
Short Interest: Healthy
3.23% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$475,690 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($1.79) to ($1.77) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

481st out of 911 stocks

Surgical & Medical Instruments Industry

55th out of 97 stocks

3.4

Analyst's Opinion

Consensus Rating
Pulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Pulmonx has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
3.23% of the float of Pulmonx has been sold short.
Short Interest Ratio / Days to Cover
Pulmonx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pulmonx has recently increased by 8.65%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Pulmonx does not currently pay a dividend.
Dividend Growth
Pulmonx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LUNG.

2.2

News and Social Media Coverage

News Sentiment
Pulmonx has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.52 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for LUNG on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pulmonx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $475,690.00 in company stock.
Percentage Held by Insiders
Only 5.70% of the stock of Pulmonx is held by insiders.
Percentage Held by Institutions
91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Pulmonx are expected to grow in the coming year, from ($1.79) to ($1.77) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pulmonx is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pulmonx is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pulmonx has a P/B Ratio of 2.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Pulmonx Stock (NASDAQ:LUNG)

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

LUNG Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LUNG Stock News Headlines

March 27, 2024 | insidertrades.com

Insider Selling: Pulmonx Co. (NASDAQ:LUNG) Insider Sells 1,184 Shares of Stock

April 12, 2024 | americanbankingnews.com

Pulmonx Co. (NASDAQ:LUNG) Given Average Recommendation of "Moderate Buy" by Brokerages

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

April 10, 2024 | globenewswire.com

Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024

April 4, 2024 | investing.com

Pulmonx names new CFO to bolster financial leadership

April 3, 2024 | markets.businessinsider.com

Navigating 6 Analyst Ratings For Pulmonx

April 2, 2024 | marketwatch.com

Pulmonx Taps Mehul Joshi as Finance Chief

April 2, 2024 | globenewswire.com

Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 17, 2024 | ca.finance.yahoo.com

LUNG Apr 2024 12.500 call

March 16, 2024 | finanznachrichten.de

Pulmonx Corporation: Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 15, 2024 | globenewswire.com

Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

March 4, 2024 | ca.finance.yahoo.com

LUNG Apr 2024 7.500 put

March 4, 2024 | ca.finance.yahoo.com

LUNG May 2024 7.500 put

March 3, 2024 | finance.yahoo.com

LUNG Aug 2024 10.000 put

March 3, 2024 | finance.yahoo.com

LUNG Apr 2024 10.000 call

March 3, 2024 | finance.yahoo.com

LUNG Aug 2024 20.000 call

March 1, 2024 | finance.yahoo.com

Steven Cohen's Point72 Asset Management Bolsters Position in Pulmonx Corp

February 26, 2024 | finanznachrichten.de

Pulmonx Corporation: Pulmonx Announces Treatment of the First Patient with the AeriSeal System in CONVERT II Pivotal Trial

February 26, 2024 | businesswire.com

Pulmonx Announces Treatment of the First Patient with the AeriSeal® System in CONVERT II Pivotal Trial

February 25, 2024 | msn.com

Pulmonx (LUNG) Price Target Increased by 7.61% to 16.83

February 24, 2024 | finance.yahoo.com

US$16.50 - That's What Analysts Think Pulmonx Corporation (NASDAQ:LUNG) Is Worth After These Results

February 23, 2024 | msn.com

Wells Fargo Downgrades Pulmonx (LUNG)

February 23, 2024 | msn.com

Pulmonx dips on Wells Fargo downgrade eyeing uncertainty over management changes

February 23, 2024 | finance.yahoo.com

Pulmonx Full Year 2023 Earnings: Beats Expectations

February 23, 2024 | realmoney.thestreet.com

Wells Fargo downgrades Pulmonx on management uncertainty

February 23, 2024 | realmoney.thestreet.com

Pulmonx just downgraded at Wells Fargo, here's why

See More Headlines

Receive LUNG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/21/2024
Today: 4/20/2024
Next Earnings (Confirmed): 5/01/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:LUNG
CUSIP: N/A
CIK: 1127537
Web: pulmonx.com
Phone: 1-650-364-0400
Fax: N/A
Employees: 279
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.83
High Stock Price Target: $18.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +110.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.60)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-60,840,000.00
Net Margins: -88.60%
Pretax Margin: -87.76%
Return on Equity: -46.63%
Return on Assets: -32.14%

Debt

Debt-to-Equity Ratio: 0.30
Current Ratio: 6.50
Quick Ratio: 5.77

Sales & Book Value

Annual Sales: $68.68 million
Price / Sales: 4.21
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.09 per share
Price / Book: 2.43

Miscellaneous

Outstanding Shares: 38,540,000
Free Float: 36,340,000
Market Cap: $289.44 million
Optionable: Optionable
Beta: 0.60

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. David A. Lehman (Age 63)
General Counsel & Secretary
Comp: $651.39k
Mr. Geoffrey Beran Rose (Age 50)
Chief Commercial Officer
Comp: $632.29k
Mr. Steven S. Williamson (Age 51)
CEO, President & Director
Mr. Mehul Joshi (Age 63)
Chief Financial Officer
Mr. Sri Radhakrishnan
Chief Technical Officer
Ms. Marcee M. Maroney (Age 54)
Vice President of Marketing
Sarah Huber
Vice President of Sales (U.S.)
Ms. Lisa Paul (Age 60)
Chief People Officer
Mr. Jérôme Erath
Senior VP & GM of Europe Middle-East & Africa
Mr. John B. McKune (Age 48)
VP & Corporate Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LUNG Stock Analysis - Frequently Asked Questions

Should I buy or sell Pulmonx stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulmonx in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LUNG shares.
View LUNG analyst ratings or view top-rated stocks.
What is Pulmonx's stock price target for 2024?: 6 brokerages have issued 12-month price objectives for Pulmonx's stock. Their LUNG share price targets range from $12.00 to $18.00. On average, they expect the company's stock price to reach $15.83 in the next twelve months. This suggests a possible upside of 110.8% from the stock's current price.
View analysts price targets for LUNG or view top-rated stocks among Wall Street analysts.
How have LUNG shares performed in 2024?: Pulmonx's stock was trading at $12.75 at the beginning of 2024. Since then, LUNG shares have decreased by 41.1% and is now trading at $7.51.
View the best growth stocks for 2024 here.
When is Pulmonx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our LUNG earnings forecast.
How can I listen to Pulmonx's earnings call?: Pulmonx will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Pulmonx's earnings last quarter?: Pulmonx Co. (NASDAQ:LUNG) posted its quarterly earnings results on Wednesday, February, 21st. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.02. The business had revenue of $19.30 million for the quarter, compared to analyst estimates of $18.24 million. Pulmonx had a negative net margin of 88.60% and a negative trailing twelve-month return on equity of 46.63%. Pulmonx's revenue for the quarter was up 25.3% on a year-over-year basis. During the same quarter last year, the company earned ($0.38) EPS.

What guidance has Pulmonx issued on next quarter's earnings?: Pulmonx issued an update on its FY 2024 earnings guidance on Wednesday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $81.0 million-$84.0 million, compared to the consensus revenue estimate of $78.9 million.
When did Pulmonx IPO?: Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley served as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers.
Who are Pulmonx's major shareholders?: Pulmonx's stock is owned by many different institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Alissa Hsu Lynch, Daniel P Florin, David Aaron Lehman, Derrick Sung, Geoffrey Beran Rose, Glendon E French III, John Mckune, Richard Ferrari and Scientific Corp Boston.
View institutional ownership trends.
How do I buy shares of Pulmonx?: Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LUNG) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pulmonx (LUNG) Stock Price, News & Analysis

Pulmonx MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

Search Interest

Company Ownership

Earnings and Valuation

About Pulmonx Stock (NASDAQ:LUNG)

LUNG Stock Price History

LUNG Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LUNG Stock Analysis - Frequently Asked Questions

Overall MarketRank^™